
    
      This is an interventional, placebo-controlled, randomized, double-blinded, dose comparison,
      phase I/II study of GalnobaxÂ® in subjects with diabetic foot ulcers. Additionally the effect
      of dosage and frequency of application will also be studied . The total trial duration per
      subject is 25 weeks which comprises of 1 week for screening, 12 weeks of treatment and 12
      weeks of follow-up.
    
  